p16INK4a lesions are common, early abnormalities that undergo clonal expansion in barrett's metaplastic epithelium

Cancer Research

Volumn 61, Issue 22, 2001, Pages 8284-8289

  Wong, D J ^a   Paulson, T G ^a   Prevo, L J ^a   Galipeau, P C ^a   Longton, G ^a   Blount, P L ^a   Reid, B J ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CARCINOGENESIS; DNA SEQUENCE; ESOPHAGUS CARCINOMA; FEMALE; FLOW CYTOMETRY; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; METAPLASIA; METHYLATION; PRIORITY JOURNAL; PROTEIN ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; BARRETT ESOPHAGUS; BIOPSY; CHROMOSOMES, HUMAN, PAIR 9; CLONE CELLS; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; EPITHELIAL CELLS; ESOPHAGEAL NEOPLASMS; HUMANS; LOSS OF HETEROZYGOSITY; METAPHASE; MIDDLE AGED; MUTATION; PRECANCEROUS CONDITIONS;

EID: 0035890616     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
2. Barrett's esophagus. Natural history, incidence, etiology, and complications
3. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease
4. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
5. Cancer cell cycles
6. Highly frequent homozygous deletion of the p16 gene in esophageal cancer cell lines
7. Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2) gene mutations in esophageal cancers
8. Genetics of human cancer
9. Frequency of homozygous deletion at p16/CDKN2 in primary human tumors
10. Frequent somatic mutations and homozygous deletions of the p16 (MTSI) gene in pancreatic adenocarcinoma
11. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus
12. Evolution of neoplastic cell lineages in Barrett's oesophagus
13. INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas
14. Mutation analysis of the p53 APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma
15. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus
16. Genetic and epigenetic alterations in normal bladder epithelium in patients with metachronous bladder cancer
17. Aberrant methylation of p16(INK4A) is an early event in lung cancer and a potential biomarker for early diagnosis
18. Early acquisition of homozygous deletions of p16/p19 during squamous cell carcinogenesis and genetic mosaicism in bladder cancer
19. Clonal genetic alterations in the lungs of current and former smokers
20. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment
21. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma
22. Epigenetic patterns in the progression of esophageal adenocarcinoma
23. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus
24. Observer variation in the diagnosis of dysplasia in Barrett's esophagus
25. Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low- and high-risk patient subsets
26. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy
27. Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR
28. Barrett's esophagus: Cell cycle abnormalities in advancing stages of neoplastic progression
29. Progressive regionspecific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest
30. Methylation-specific, P. C. R. a novel PCR assay for methylation status of CpG islands
31. (ARF) is independent of p16(INK4A) methylation and p53 mutational status
32. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue
33. A Wilcoxon-type test for trend
34. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: Prospective endoscopic surveillance of a cohort
35. Predictors of progression in Barrett's esophagus: Baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression
36. High frequency of p16 (CDKN2/MTS-1/1NK4A) inactivation in head and neck squamous cell carcinoma
37. Clonal origin of bladder cancer
38. Genetic progression model for head and neck cancer: Implications for field cancerization
39. Genomic structure, expression and mutational analysis of the p15 (MTS2) gene
40. A gene hypermethylation profile of human cancer
41. Hypermethylation-associated inactivation indicates a tumor suppressor role for p151NK4B
42. Involvement of the cyclin-dependent kinase inhibitor p16 (1NK4A) in replicative senescence of normal human fibroblasts
43. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence
44. Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells
45. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4A
46. Inactivation of p16 in human mammary epithelial cells by CpG island methylation
47. The murine gene p27Kipl is haplo-insufficient for tumour suppression
48. Correlation of oesophageal acid exposure with Barrett's oesophagus length
49. The extent of Barrett's esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure
50. Effect of segment length on the risk of neoplastic progression in patients with Barrett's esophagus
51. Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus
52. Prospective study of cyclin D1 overexpression in Barrett's esophagus: Association with increased risk of adenocarcinoma
53. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
54. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition
55. Expression of cyclin D1, CDK4 and p27KIPI is associated with the p16MTSI gene status in human esophageal carcinoma cell lines